Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
8 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Efficacy and Cardiovascular Adverse Events of Long-term Treatment with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Report from the Nagasaki CML Study Group.
Intern Med. 2021 Jul 15;60(14):2207-2216. doi: 10.2169/internalmedicine.6620-20. Epub 2021 Feb 22.
Intern Med. 2021.
PMID: 33612681
Free PMC article.
No clear survival benefit of azacitidine for lower-risk myelodysplastic syndromes: A retrospective study of Nagasaki.
Toriyama E, Hata T, Yokota KI, Chiwata M, Kamijo R, Hashimoto M, Taguchi M, Horai M, Matsuo M, Matsuo E, Takasaki Y, Kawaguchi Y, Itonaga H, Sato S, Ando K, Sawayama Y, Taguchi J, Imaizumi Y, Tsushima H, Jo T, Yoshida S, Moriuchi Y, Miyazaki Y.
Toriyama E, et al. Among authors: yokota ki.
Cancer Sci. 2020 Dec;111(12):4490-4499. doi: 10.1111/cas.14653. Epub 2020 Oct 23.
Cancer Sci. 2020.
PMID: 32939867
Free PMC article.
Item in Clipboard
Relationship between monoclonal gammopathy of undetermined significance and radiation exposure in Nagasaki atomic bomb survivors.
Iwanaga M, Tagawa M, Tsukasaki K, Matsuo T, Yokota K, Miyazaki Y, Fukushima T, Hata T, Imaizumi Y, Imanishi D, Taguchi J, Momita S, Kamihira S, Tomonaga M.
Iwanaga M, et al.
Blood. 2009 Feb 19;113(8):1639-50. doi: 10.1182/blood-2008-05-159665. Epub 2008 Oct 10.
Blood. 2009.
PMID: 18849487
Free article.
Item in Clipboard
Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial.
Miyazaki Y, Kiguchi T, Sato S, Usuki K, Ishiyama K, Ito Y, Suzuki T, Taguchi J, Chiba S, Dobashi N, Tomita A, Harada H, Handa H, Horiike S, Maeda T, Matsuda M, Ichikawa M, Hata T, Honda S, Iyama S, Suzushima H, Moriuchi Y, Kurokawa T, Yokota K, Ohtake S, Yamauchi T, Matsumura I, Kiyoi H, Naoe T; Japan Adult Leukemia Study Group.
Miyazaki Y, et al.
Int J Hematol. 2022 Aug;116(2):228-238. doi: 10.1007/s12185-022-03347-3. Epub 2022 May 4.
Int J Hematol. 2022.
PMID: 35508695
Clinical Trial.
Item in Clipboard
The Nagasaki Atomic Bomb Survivors' Tumor Tissue Bank.
Miura S, Akazawa Y, Kurashige T, Tukasaki K, Kondo H, Yokota K, Mine M, Miyazaki Y, Sekine I, Nakashima M.
Miura S, et al.
Lancet. 2015 Oct 31;386(10005):1738. doi: 10.1016/S0140-6736(15)00698-4.
Lancet. 2015.
PMID: 26545440
No abstract available.
Item in Clipboard
Effects of radiation on the incidence of prostate cancer among Nagasaki atomic bomb survivors.
Kondo H, Soda M, Mine M, Yokota K.
Kondo H, et al.
Cancer Sci. 2013 Oct;104(10):1368-71. doi: 10.1111/cas.12234. Epub 2013 Aug 12.
Cancer Sci. 2013.
PMID: 23859763
Free PMC article.
Item in Clipboard
Future population of atomic bomb survivors in Nagasaki.
Yokota K, Mine M, Shibata Y.
Yokota K, et al.
Stud Health Technol Inform. 2013;192:952.
Stud Health Technol Inform. 2013.
PMID: 23920726
Item in Clipboard
Cancer mortality in residents of the terrain-shielded area exposed to fallout from the Nagasaki atomic bombing.
Yokota K, Mine M, Kondo H, Matsuda N, Shibata Y, Takamura N.
Yokota K, et al.
J Radiat Res. 2018 Jan 1;59(1):1-9. doi: 10.1093/jrr/rrx047.
J Radiat Res. 2018.
PMID: 29036510
Free PMC article.
Item in Clipboard
Cite
Cite